Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas

By sjmartinez • January 28, 2025

Wilky BA, Schwartz GK, Gordon MS, El-Khoueiry AB, Bullock AJ, Henick B, Agulnik M, Singh A, Mahadevan D, Stebbing J, Delepine C, Chand D, Avagyan M, Wu W, Johnson B, Grossman JE, O'Day S, Trent JC, Jones RL, Tsimberidou AM. Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas. J Clin Oncol. 2025 Jan 27:JCO2402524. doi: 10.1200/JCO-24-02524. Epub ahead of print. PMID: 39869830.

Tags: Hematology/Oncology, Publications

PAK4 orchestrates dual transcriptional and post-translational repression of E-cadherin to promote epithelial-to-mesenchymal transition and invasiveness in pancreatic cancer

Kim KJ, Lee CH, Nam M, Na HY, Sung JH, Park BR, Hwang SH, Park W, Seo J, Kang M, Jung EH, Kim SA, Suh[...]

Discussing lung cancer management options in the emergency department

Moghanaki D, Goldman J, Weingrow D, Hendey GW. Discussing lung cancer management options in the emergency department. Emerg Med J. 2026 Oct 30:emermed-2026-216560. doi: 10.1136/emermed-2026-216560.[...]

p53 activation via pharmacologic MDM2 inhibition constrains exhaustion and enhances antitumor function of human CD8+ T cells

Boix de Jesus A, Dao HB, Imani A, Rodriguez GA, Shehata MS, Chandran RR, Fine SA, Lim SY, To M, Lofftus SY, Pedroncelli N, Eilber[...]